Physician profile
Gary S Becker
NPI 1164439964
$22,572.47
in general payments reported to CMS, 2019-2025
56 companies · $5,006 in 2025
The $5,006 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,076 · 2020: $1,331 · 2021: $2,023 · 2022: $1,254 · 2023: $5,420 · 2024: $6,463 · 2025: $5,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,200 · Consulting Fee: $350 · Travel and Lodging: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,216.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,200.00 |
| Consulting Fee | $350.00 |
| Travel and Lodging | $122.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $8,624.08 | 2021-2025 | Afrezza, V-Go |
| Abbott Laboratories | $2,590.73 | 2023-2025 | Aveir, Gallant, Optis |
| Astrazeneca Pharmaceuticals Lp | $1,019.16 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $880.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $797.61 | 2019-2025 | Vraylar, Linzess, Creon |
| Novo Nordisk INC | $794.01 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $634.11 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $618.03 | 2019-2025 | Verquvo, Lagevrio, Capvaxive |
| Janssen Pharmaceuticals, INC | $566.63 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $516.05 | 2022-2025 | Avvigo Guidance System, General - Therapies |
| Shockwave Medical, INC | $490.22 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $421.41 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Dexcom, INC. | $415.46 | 2021-2024 | Dexcom G6 Transmitter |
| Medimetriks Pharmaceuticals, INC. | $350.00 | 2025 | Genadur, Neo-Synalar |
| E.R. Squibb & Sons, L.L.C. | $317.25 | 2020-2024 | Cobenfy, Eliquis, Camzyos |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.